The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     
 


Published online June 24, 2009
The Journal of Immunology, 2009, doi:10.4049/jimmunol.0803671
Copyright © 2009 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text (PDF)
Right arrow [Data Supplement] 
Right arrow [Extended Methods]
Right arrow All Versions of this Article:
jimmunol.0803671v1
183/2/1110    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Leavenworth, J. W.
Right arrow Articles by Pauza, M. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leavenworth, J. W.
Right arrow Articles by Pauza, M. E.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Protein
*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*L-LYSINE

SUMO Conjugation Contributes to Immune Deviation in Nonobese Diabetic Mice by Suppressing c-Maf Transactivation of IL-41

Jianmei W. Leavenworth*, Xiaojing Ma{ddagger}, Yin-yuan Mo* and Mary E. Pauza*,{dagger},2

*Department of Medical Microbiology, Immunology, and Cell Biology {dagger}Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield, IL 62702; and {ddagger}Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021

It is not clear why the development of protective Th2 cells is poor in type 1 diabetes (T1D). c-Maf transactivates the IL-4 gene promoting Th2 cell development; therefore, abnormalities in c-Maf may contribute to reduced IL-4 production by CD4 cells from nonobese diabetic (NOD) mice. In this study we demonstrate that despite normal expression, c-Maf binds poorly to the IL-4 promoter (IL-4p) in NOD CD4 cells. Immunoblotting demonstrates that c-Maf can be modified at lysine 33 by SUMO-1 (small ubiquitin-like modifier 1). Sumoylation is facilitated by direct interaction with the E2-conjugating enzyme Ubc9 and increases following T cell stimulation. In transfected cells, sumoylation decreases c-Maf transactivation of IL-4p-driven luciferase reporter activity, reduces c-Maf binding to the IL-4p in chromatin immunoprecipitation assays, and enhances c-Maf localization into promyelocytic leukemia nuclear bodies. Sumoylation of c-Maf is increased in NOD CD4 cells as compared with CD4 cells from diabetes-resistant B10.D2 mice, suggesting that increased c-Maf sumoylation contributes to immune deviation in T1D by reducing c-Maf access to and transactivation of the IL-4 gene.

2 Address correspondence and reprint requests to Dr. Mary E. Pauza, Medical Microbiology, Immunology, and Cell Biology, Southern Illinois University School of Medicine, 825 North Rutledge, P. O. Box 19626, Springfield, IL 62794. E-mail address: mpauza{at}siumed.edu

1 This work was supported by grants from the Juvenile Diabetes Research Foundation and the Southern Illinois University Central Research Committee (to M.E.P.).







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This Website Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.